Results 221 to 230 of about 35,506 (340)

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

open access: yesAdvanced Science, EarlyView.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang   +7 more
wiley   +1 more source

Disrupting CSPG‐Driven Microglia–Astrocyte Crosstalk Enables Scar‐Free Repair in Spinal Cord Injury

open access: yesAdvanced Science, EarlyView.
This study identifies CSPGs as key drivers of glial scar maturation after spinal cord injury by reprogramming microglial metabolism and inducing astrocyte fibrosis. To address this, a reactive oxygen species‐responsive, reactive astrocyte‐targeted ChABC gene delivery system is designed to locally degrade CSPGs, precisely disrupt maladaptive glial ...
Yufei Zheng   +10 more
wiley   +1 more source

Photothermal Transport for Guiding Nanoparticles Through the Vitreous Humor

open access: yesAdvanced Science, EarlyView.
Nanosecond laser irradiation of the clinically approved dye indocyanine green (ICG) enables light‐guided nanoparticle transport within the vitreous humor. The combined use of ICG and pulsed laser illumination induces localized convection and thermophoresis, directing particles toward illuminated regions.
Léa Guerassimoff   +9 more
wiley   +1 more source

NIR Ratiometric Fluorescent Antibody‐Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring

open access: yesAdvanced Science, EarlyView.
In vivo optical imaging enhances antibody‐drug conjugate (ADC) optimization by enabling real‐time monitoring of stimulus‐responsive drug behavior. We report n501‐CYMMAF, a ratiometric theranostic with strong target affinity and low‐dose efficacy for ovarian metastasis.
Cheng Li   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy